Dec. 13 at 3:40 PM
$CAPR lets discuss bo potential.
when do you think it will happen and who will be the buyer?
Keep in mind that In essence, the sweet spot for a biotech company is when its lead asset has demonstrated strong human efficacy data, maximizing its value to potential acquirers.
By the way I was spot on when Aveo
$CCXI $RXDX $CDTX where bought out. I was wrong w
$TGTX but that worked out pretty good too!
Most bo targets have compelling late stage trial results followed by offering after huge gap up that never closes the gap, continues to hold above the offering price and may even continue to trend up as tutes accumulate shares.
Sound familiar?
